Saturday , March 6 2021

NCI-MATCH Patients with AKT1-mutated Cancer Responses to AstraZeneca Medication



  1. NCI-MATCH patients with AKT1-mutated cancer respond to AstraZeneca's drug genomeWeb
  2. Medicines that are matched to tumor gene testing in patients suggest that EurekAlert is effective (press release)
  3. Full coverage


Source link